Abstract: The present invention is directed to antigen binding proteins and in particular to IL-1? antigen binding proteins. The present invention further provides compositions comprising the antigen binding proteins, use of the antigen binding proteins and methods for production.

Abstract: Anti-CD122 and/or ?c antibodies and fragments thereof are disclosed. Also disclosed are compositions comprising such antibodies and fragments, and uses and methods using the same.

Abstract: Embodiments of the present invention relate to automatically identifying structures of a music stream. A segment structure may be generated that visually indicates repeating segments of a music stream. To generate a segment structure, a feature that corresponds to a music attribute from a waveform corresponding to the music stream is extracted from a waveform, such as an input signal. Utilizing a signal segmentation algorithm, such as a Variable Markov Oracle (VMO) algorithm, a symbolized signal, such as a VMO structure, is generated. From the symbolized signal, a matrix is generated. The matrix may be, for instance, a VMO-SSM. A segment structure is then generated from the matrix. The segment structure illustrates a segmentation of the music stream and the segments that are repetitive.

Abstract: Anti-CD122 and/or ?c antibodies and fragments thereof are disclosed. Also disclosed are compositions comprising such antibodies and fragments, and uses and methods using the same.

Abstract: Embodiments of the present invention relate to automatically identifying structures of a music stream. A segment structure may be generated that visually indicates repeating segments of a music stream. To generate a segment structure, a feature that corresponds to a music attribute from a waveform corresponding to the music stream is extracted from a waveform, such as an input signal. Utilizing a signal segmentation algorithm, such as a Variable Markov Oracle (VMO) algorithm, a symbolized signal, such as a VMO structure, is generated. From the symbolized signal, a matrix is generated. The matrix may be, for instance, a VMO-SSM. A segment structure is then generated from the matrix. The segment structure illustrates a segmentation of the music stream and the segments that are repetitive.

Abstract: Anti-CD122 and/or ?c antibodies and fragments thereof are disclosed. Also disclosed are compositions comprising such antibodies and fragments, and uses and methods using the same.

Abstract: Anti-CD122 and/or ?c antibodies and fragments thereof are disclosed. Also disclosed are compositions comprising such antibodies and fragments, and uses and methods using the same.

Abstract: Anti-CD122 and/or ?c antibodies and fragments thereof are disclosed. Also disclosed are compositions comprising such antibodies and fragments, and uses and methods using the same.

Abstract: Disclosed are isolated antibodies, or antigen binding fragments thereof, that bind to dengue virus epitopes, as well as kits containing them, compositions containing them, and passive vaccines comprising them, in one embodiment, the antibody or antigen binding fragment thereof is capable of binding to a whole dengue virus particle better than binding to a dengue virus surface glycoprotein. Also disclosed are methods of using the antibodies or antigen binding fragments thereof, nucleic acids encoding them, vectors expressing the nucleic acids, host producing them, and methods of manufacturing them.

Abstract: Anti-PD-L1 antibodies are disclosed. Also disclosed are pharmaceutical compositions comprising such antibodies, and methods of using such antibodies to restore T-cell function in T-cells exhibiting T-cell exhaustion or T-cell anergy.

Abstract: Anti-PD-L1 antibodies are disclosed. Also disclosed are pharmaceutical compositions comprising such antibodies, and uses and methods using the same.

Abstract: Anti-PD-1 antibodies are disclosed. Also disclosed are pharmaceutical compositions comprising such antibodies, and uses and methods using the same.

Abstract: Anti-TIM-3 antibodies are disclosed, as well as pharmaceutical compositions comprising such antibodies, and uses and methods using the same, such as in the treatment of cancer or infectious disease or T-cell dysfunctional disorders. Bispecific antibodies against TIM-3 and other targets are also disclosed, with a preferred embodiment of a bispecific antibody against TIM-3 and CD3.

Abstract: Anti-PD-L1 antibodies are disclosed. Also disclosed are pharmaceutical compositions comprising such antibodies, and uses and methods using the same.

Abstract: Anti-PD-1 antibodies are disclosed. Also disclosed are pharmaceutical compositions comprising such antibodies, and uses and methods using the same.

Abstract: Anti-CTLA-4 antibodies are disclosed. Also disclosed are compositions comprising such antibodies, and uses and methods using the same.

Abstract: Anti-PD-1 antibodies are disclosed. Also disclosed are pharmaceutical compositions comprising such antibodies, and uses and methods using the same.

Abstract: Anti-TIM-3 antibodies are disclosed, as well as pharmaceutical compositions comprising such antibodies, and uses and methods using the same, such as in the treatment of cancer, infectious diseases, or T-cell dysfunctional disorders. Bispecific antibodies against TIM-3 and other targets are also disclosed, with preferred embodiment of a bispecific antibody against TIM-3 and CD3.

Abstract: The invention relates to binding molecules against Chikungunya virus, which are able of neutralizing Chikungunya virus infectivity, and which can be used with therapeutic, diagnosis or research purposes, as well as to a pharmaceutical composition comprising said binding molecules.

Abstract: Anti-CTLA-4 antibodies are disclosed. Also disclosed are compositions comprising such antibodies, and uses and methods using the same.